All articles
Semaglutide vs. Ozempic: Understanding the Differences for Weight Loss
Reading time:
5 min
Weight loss

Get expert guidance and a personalized care plan designed around you.
Side Effects Comparison
When comparing the side effects of compounded Semaglutide and Ozempic®, it's notable that they share a very similar, if not identical, profile (3,4,5). Both medications can cause gastrointestinal issues as the most common side effects, such as:
Nausea
Vomiting
Diarrhea
Constipation
However, it's essential to recognize that the severity and frequency of these side effects can vary from one individual to another. In addition to these gastrointestinal symptoms, other common side effects may include:
Headaches
Abdominal discomfort or pain
Loss of appetite
Fatigue or weakness
Skin irritation at the injection site
While these side effects are generally mild to moderate and tend to diminish over time as the body adjusts to the medication, there are also some rarer but potentially more severe side effects that individuals should be aware of, including:
Hypoglycemia (low blood sugar)
Pancreatitis
Allergic reactions
Thyroid tumors
Getting Started On Semaglutide or Ozempic
If you're interested in starting either Ozempic® or compounded semaglutide, it's important to consult a healthcare provider to obtain a valid prescription. Avoid websites or sources that offer these medications without a prescription.
To get started, find out if you’re eligible for the comprehensive obesity medicine program at Mochi Health. Our licensed healthcare providers are ready to create personalized treatment plans that include the latest advancements in weight loss medications, including Ozempic®, Wegovy®, and Compounded Semaglutide. Let us help you embark on your journey towards a healthier you.
References:
https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
Ghusn, W., De la Rosa, A., Sacoto, D., Cifuentes, L., Campos, A., Feris, F., Hurtado, M. D., & Acosta, A. (2022). Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Network Open, 5(9), e2231982–e2231982. https://doi.org/10.1001/jamanetworkopen.2022.31982
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., Wallenstein, S. O. R., & Garvey, W. T. (2021). Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA : The Journal of the American Medical Association, 325(14), 1403–1413. https://doi.org/10.1001/jama.2021.1831
This post was written by our team of health writers for informational purposes only and does not constitute medical advice. Always consult your doctor or healthcare provider for personalized guidance regarding your health. Ozempic®, Wegovy®, Mounjaro®, and Zepbound® and their delivery device are registered trademarks. Mochi Health is a telehealth clinic that offers prescriptions for these products by medical necessity only as determined by a licensed health provider.
Share this post
Weight loss
More articles















